ONCR 148
Alternative Names: ONCR-148Latest Information Update: 28 Apr 2023
At a glance
- Originator Oncorus
- Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Antibody-dependent cell cytotoxicity; Gene transference; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for preclinical development in Solid-tumours in USA (Intratumoural)
- 08 Apr 2019 Oncorus has patent protection for HSV platform (Ocorus website, April 2019)
- 01 Apr 2019 Pharmacodynamics data from preclinical studies in Solid tumours released by Oncorus